Case Study: AI Found 29% More Breast Cancers by Not Replacing Doctors
Inside the MASAI trial: 100,000 mammograms, 29% more cancers caught, 44% less radiologist workload.
A woman in Sweden went for a mammogram she had been to a dozen times before. Two pictures, a few minutes, the same waiting room. Her results were analysed the same way they always are: by two sets of eyes.
Except one of those readers was a piece of software, and it lingered on a faint asymmetry a tired radiologist might have let pass at the end of a long list. A doctor looked again because the machine had flagged it. The cancer was small and early and treatable. Caught now, on the screen, instead of eighteen months later as a lump she found herself, by which point it would have been a different disease with different odds.
That is an example of a story people will tell the wrong way around.
It arrives as the proof we have all been waiting for: the machine that reads scans better than the doctor, the first hard evidence that AI can finally do the radiologist’s job. A randomised trial, a hundred thousand women, a number. 29% more cancers found! The headline writes itself, and it is to refute the headline that I write this.
The trial that actually worked did the opposite of what the headline says
I refute it because the deployment that produced that number was built, deliberately, as the inverse of replacing the doctor.
The AI in the MASAI trial never gave a verdict! It did two humble things:
It sorted the screening list, setting aside the films that were plainly clear so the radiologists’ hours went to the ones that were not.
And it acted as a second reader, a tireless one, flagging the faint thing on the film for a human to look at again.
On every case that mattered, a radiologist still read the picture and made the call. No cancer was ever quietly dismissed by a machine.
That is the whole of why it worked. The human replacement story, the one where the model reads your scan and the doctor goes home, is precisely the thing that does not survive contact with the trial that actually delivered.
What WAS delivered was the model kept on a leash, doing the dull half of the radiologist’s job so she could do the hard half better.
MASAI was a randomised controlled trial run across a Swedish screening population of more than a hundred thousand women, the first of its kind, with the full results published in The Lancet this January. A trial, using the same instrument we use to decide whether a drug works, pointed at a question about software.
And it found this:
29% more cancers detected in the group whose mammograms the AI helped read.
Sensitivity, the share of real cancers the screening actually catches, rose from 73.8% to 80.5%, and it rose at the same specificity (which is the technical way of saying the extra catches did not come at the cost of a flood of false alarms calling healthy women back in fear). More found, not more frightened.
The finding that decides whether women live
But more cancers is not even the most important part.
Catching more cancers can, in the wrong design, just mean catching more of the harmless ones, the slow tumours a woman would have died with rather than from. That is not what happened here. The AI-supported arm had 12% fewer interval cancers, the ones that surface painfully between screening rounds because the last scan missed them. And it got there with no rise in false positives. Fewer missed, not more recalled.
And the cancers it caught earlier were the ones that matter most. Twenty-seven per cent fewer of the aggressive, fast-growing tumours - the non-luminal-A subtype - were surfacing as interval cancers, because they were being caught on the screen instead. That is the finding that actually bears weight on whether women live, and it is the one most write-ups skated past on their way to the bigger, rounder twenty-nine.
And it bought back the scarcest thing in the building
The other half of the win is the half a hospital administrator actually signs the cheque for. The interim safety read-out, reported back in 2023 before the detection results were in, found the AI cut the radiologists’ screen-reading workload by forty-four per cent. Nearly half the reading, gone.
It is easy to hear that as a layoffs number, and it is the opposite of one. The radiologists did not leave. There were not fewer of them. There was the same scarce, expensive, finite human attention, no longer spread in a thin even film across a thousand normal breasts, but concentrated on the handful of images where a trained eye changes an outcome. Radiologists are not a commodity you can conjure; most health systems are short of them and have been for years. The forty-four per cent is not heads cut. It is attention returned, to the people who already had too little of it.
Why this one delivered when the others flopped
Step back from the cancer and the % numbers and look at the shape, because the shape is the transferable thing.
Plenty of medical-AI pilots have died quietly:
the ones that tried to be the diagnostician,
that posted a benchmark score and called it proof,
that went straight to the customer-facing front of the queue.
MASAI did three things at once that those did not.
It was validated before it scaled, in a randomised trial, not waved through on a demo and a hope.
The human was kept on every consequential read, so the model’s mistakes had somewhere to land that was not a patient.
And it was wired to the two numbers a screening programme is genuinely funded and judged on, the cancers it detects and the reading hours it has, rather than to a benchmark that impresses a conference and moves nothing on the ground.
That conjunction is the win. The deployment being built right.
What a win actually looks like
So here is the picture to keep.
A radiologist sits down to her list. It’s shorter than it used to be, because something cleared the easy films overnight.
On the ones that remain, a second reader that never tires has already pointed at the faint, the easily missed, the thing at the end of a long day. She looks harder where looking hard counts. A woman goes home with a cancer found early instead of late.